Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21796103 | 0.99 | ELANE (0.46) | ELANEMEN1KMT2APOLBMGAT2 | |
| Benzene SCHEMBL19640005 | 0.88 | ELANE (0.46) | ELANEMEN1KMT2APOLBVNN1 | |
| SCHEMBL21796091 | 0.88 | ELANE (0.47) | ELANEMEN1KMT2AVNN1P2RY1 | |
| Benzene SCHEMBL19639976 | 0.87 | ELANE (0.46) | ELANEMEN1KMT2A | |
| Benzene SCHEMBL19640062 | 0.86 | ELANE (0.44) | ELANEMEN1KMT2A | |
| SCHEMBL21796099 | 0.85 | ELANE (0.45) | ELANEMEN1KMT2A | |
| Benzene SCHEMBL19639999 | 0.85 | ELANE (0.43) | ELANE | |
| SCHEMBL21796094 | 0.84 | ELANE (0.44) | ELANE | |
| Benzene SCHEMBL19639962 | 0.83 | ELANE (0.47) | ELANEMEN1KMT2APOLB | |
| SCHEMBL21796131 | 0.83 | ELANE (0.47) | ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | claimed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | claimed |
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| EP-3464268-A1 | NOVEL COMPOUNDS | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017207432-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885MEN1 4540/4885KMT2A 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.